The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)

Christoph Seidel; Gedske Daugaard; Tim Nestler; Alexey Tryakin; Mikhail Fedyanin; Christian Daniel Fankhauser; Thomas Hermanns; Jorge Aparicio; Julia Heinzelbecker; Pia Paffenholz; Axel Heidenreich; Ugo De Giorgi; Richard Cathomas; Anja Lorch; Anna Fingerhut; Fabian Gayer; Felix Bremmer; Patrizia Giannatempo; Andrea Necchi; Daniele Raggi; Gaetano Aurilio; Chiara Casadei; Marcus Hentrich; Ben Tran; Klaus-Peter Dieckmann; Margarido Brito; Christian Ruf; Alessandro Mazzocca; Bruno Vincenzi; Olof Stahl; Carsten Bokemeyer; Christoph Oing

doi:10.1007/s00345-021-03635-3

The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)

Christoph Seidel, Gedske Daugaard, Tim Nestler, Alexey Tryakin, Mikhail Fedyanin, Christian Daniel Fankhauser, Thomas Hermanns, Jorge Aparicio, Julia Heinzelbecker, Pia Paffenholz, Axel Heidenreich, Ugo De Giorgi, Richard Cathomas, Anja Lorch, Anna Fingerhut, Fabian Gayer, Felix Bremmer, Patrizia Giannatempo, Andrea Necchi, Daniele RaggiGaetano Aurilio, Chiara Casadei, Marcus Hentrich, Ben Tran, Klaus-Peter Dieckmann, Margarido Brito, Christian Ruf, Alessandro Mazzocca, Bruno Vincenzi, Olof Stahl, Carsten Bokemeyer, Christoph Oing

Department of Oncology

Abstract

PURPOSE: The prognostic significance of lactate dehydrogenase (LDH) in patients with metastatic seminoma is not defined. We investigated the prognostic impact of LDH levels prior to first-line systemic treatment and other clinical characteristics in this subset of patients.

METHODS: Files from two registry studies and one single-institution database were analyzed retrospectively. Uni- and multivariate analyses were conducted to identify patient characteristics associated with recurrence free survival (RFS), overall survival (OS), and complete response rate (CRR).

RESULTS: The dataset included 351 metastatic seminoma patients with a median follow-up of 5.36 years. Five-year RFS, OS and CRR were 82%, 89% and 52%, respectively. Explorative analysis revealed a cut-off LDH level of < 2.5 upper limit of normal (ULN) (n = 228) vs. ≥ 2.5 ULN (n = 123) to be associated with a significant difference concerning OS associated with 5-years OS rates of 93% vs. 83% (p = 0.001) which was confirmed in multivariate analysis (HR 2.87; p = 0.004). Furthermore, the cut-off LDH < 2.5 ULN vs. ≥ 2.5 ULN correlated with RFS and CRR associated with a 5-years RFS rate and CRR of 76% vs. 86% (p = 0.012) and 32% vs. 59% (p ≤ 0.001), respectively.

CONCLUSIONS: LDH levels correlate with treatment response and survival in metastatic seminoma patients and should be considered for their prognostic stratification.

Original language	English
Journal	World Journal of Urology
Volume	39
Issue number	9
Pages (from-to)	3407-3414
Number of pages	8
ISSN	0724-4983
DOIs	https://doi.org/10.1007/s00345-021-03635-3
Publication status	Published - Sept 2021

Keywords

Adolescent
Adult
Aged
Humans
L-Lactate Dehydrogenase/blood
Male
Middle Aged
Neoplasm Staging
Prognosis
Retrospective Studies
Seminoma/blood
Survival Rate
Testicular Neoplasms/blood
Young Adult

Access to Document

10.1007/s00345-021-03635-3

Cite this

Seidel, C., Daugaard, G., Nestler, T., Tryakin, A., Fedyanin, M., Fankhauser, C. D., Hermanns, T., Aparicio, J., Heinzelbecker, J., Paffenholz, P., Heidenreich, A., De Giorgi, U., Cathomas, R., Lorch, A., Fingerhut, A., Gayer, F., Bremmer, F., Giannatempo, P., Necchi, A., ... Oing, C. (2021). The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). World Journal of Urology, 39(9), 3407-3414. https://doi.org/10.1007/s00345-021-03635-3

The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). / Seidel, Christoph; Daugaard, Gedske; Nestler, Tim et al.
In: World Journal of Urology, Vol. 39, No. 9, 09.2021, p. 3407-3414.

Research output: Contribution to journal › Journal article › Research › peer-review

Seidel, C, Daugaard, G, Nestler, T, Tryakin, A, Fedyanin, M, Fankhauser, CD, Hermanns, T, Aparicio, J, Heinzelbecker, J, Paffenholz, P, Heidenreich, A, De Giorgi, U, Cathomas, R, Lorch, A, Fingerhut, A, Gayer, F, Bremmer, F, Giannatempo, P, Necchi, A, Raggi, D, Aurilio, G, Casadei, C, Hentrich, M, Tran, B, Dieckmann, K-P, Brito, M, Ruf, C, Mazzocca, A, Vincenzi, B, Stahl, O, Bokemeyer, C & Oing, C 2021, 'The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)', World Journal of Urology, vol. 39, no. 9, pp. 3407-3414. https://doi.org/10.1007/s00345-021-03635-3

@article{09ee78249d0e45bfa5f94b691c046edf,

title = "The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)",

abstract = "PURPOSE: The prognostic significance of lactate dehydrogenase (LDH) in patients with metastatic seminoma is not defined. We investigated the prognostic impact of LDH levels prior to first-line systemic treatment and other clinical characteristics in this subset of patients.METHODS: Files from two registry studies and one single-institution database were analyzed retrospectively. Uni- and multivariate analyses were conducted to identify patient characteristics associated with recurrence free survival (RFS), overall survival (OS), and complete response rate (CRR).RESULTS: The dataset included 351 metastatic seminoma patients with a median follow-up of 5.36 years. Five-year RFS, OS and CRR were 82%, 89% and 52%, respectively. Explorative analysis revealed a cut-off LDH level of < 2.5 upper limit of normal (ULN) (n = 228) vs. ≥ 2.5 ULN (n = 123) to be associated with a significant difference concerning OS associated with 5-years OS rates of 93% vs. 83% (p = 0.001) which was confirmed in multivariate analysis (HR 2.87; p = 0.004). Furthermore, the cut-off LDH < 2.5 ULN vs. ≥ 2.5 ULN correlated with RFS and CRR associated with a 5-years RFS rate and CRR of 76% vs. 86% (p = 0.012) and 32% vs. 59% (p ≤ 0.001), respectively.CONCLUSIONS: LDH levels correlate with treatment response and survival in metastatic seminoma patients and should be considered for their prognostic stratification.",

keywords = "Adolescent, Adult, Aged, Humans, L-Lactate Dehydrogenase/blood, Male, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Seminoma/blood, Survival Rate, Testicular Neoplasms/blood, Young Adult",

author = "Christoph Seidel and Gedske Daugaard and Tim Nestler and Alexey Tryakin and Mikhail Fedyanin and Fankhauser, {Christian Daniel} and Thomas Hermanns and Jorge Aparicio and Julia Heinzelbecker and Pia Paffenholz and Axel Heidenreich and {De Giorgi}, Ugo and Richard Cathomas and Anja Lorch and Anna Fingerhut and Fabian Gayer and Felix Bremmer and Patrizia Giannatempo and Andrea Necchi and Daniele Raggi and Gaetano Aurilio and Chiara Casadei and Marcus Hentrich and Ben Tran and Klaus-Peter Dieckmann and Margarido Brito and Christian Ruf and Alessandro Mazzocca and Bruno Vincenzi and Olof Stahl and Carsten Bokemeyer and Christoph Oing",

note = "{\textcopyright} 2021. The Author(s).",

year = "2021",

month = sep,

doi = "10.1007/s00345-021-03635-3",

language = "English",

volume = "39",

pages = "3407--3414",

journal = "World Journal of Urology",

issn = "0724-4983",

publisher = "Springer",

number = "9",

}

TY - JOUR

T1 - The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease

T2 - an analysis by the Global Germ Cell Tumor Collaborative Group (G3)

AU - Seidel, Christoph

AU - Daugaard, Gedske

AU - Nestler, Tim

AU - Tryakin, Alexey

AU - Fedyanin, Mikhail

AU - Fankhauser, Christian Daniel

AU - Hermanns, Thomas

AU - Aparicio, Jorge

AU - Heinzelbecker, Julia

AU - Paffenholz, Pia

AU - Heidenreich, Axel

AU - De Giorgi, Ugo

AU - Cathomas, Richard

AU - Lorch, Anja

AU - Fingerhut, Anna

AU - Gayer, Fabian

AU - Bremmer, Felix

AU - Giannatempo, Patrizia

AU - Necchi, Andrea

AU - Raggi, Daniele

AU - Aurilio, Gaetano

AU - Casadei, Chiara

AU - Hentrich, Marcus

AU - Tran, Ben

AU - Dieckmann, Klaus-Peter

AU - Brito, Margarido

AU - Ruf, Christian

AU - Mazzocca, Alessandro

AU - Vincenzi, Bruno

AU - Stahl, Olof

AU - Bokemeyer, Carsten

AU - Oing, Christoph

PY - 2021/9

Y1 - 2021/9

N2 - PURPOSE: The prognostic significance of lactate dehydrogenase (LDH) in patients with metastatic seminoma is not defined. We investigated the prognostic impact of LDH levels prior to first-line systemic treatment and other clinical characteristics in this subset of patients.METHODS: Files from two registry studies and one single-institution database were analyzed retrospectively. Uni- and multivariate analyses were conducted to identify patient characteristics associated with recurrence free survival (RFS), overall survival (OS), and complete response rate (CRR).RESULTS: The dataset included 351 metastatic seminoma patients with a median follow-up of 5.36 years. Five-year RFS, OS and CRR were 82%, 89% and 52%, respectively. Explorative analysis revealed a cut-off LDH level of < 2.5 upper limit of normal (ULN) (n = 228) vs. ≥ 2.5 ULN (n = 123) to be associated with a significant difference concerning OS associated with 5-years OS rates of 93% vs. 83% (p = 0.001) which was confirmed in multivariate analysis (HR 2.87; p = 0.004). Furthermore, the cut-off LDH < 2.5 ULN vs. ≥ 2.5 ULN correlated with RFS and CRR associated with a 5-years RFS rate and CRR of 76% vs. 86% (p = 0.012) and 32% vs. 59% (p ≤ 0.001), respectively.CONCLUSIONS: LDH levels correlate with treatment response and survival in metastatic seminoma patients and should be considered for their prognostic stratification.

AB - PURPOSE: The prognostic significance of lactate dehydrogenase (LDH) in patients with metastatic seminoma is not defined. We investigated the prognostic impact of LDH levels prior to first-line systemic treatment and other clinical characteristics in this subset of patients.METHODS: Files from two registry studies and one single-institution database were analyzed retrospectively. Uni- and multivariate analyses were conducted to identify patient characteristics associated with recurrence free survival (RFS), overall survival (OS), and complete response rate (CRR).RESULTS: The dataset included 351 metastatic seminoma patients with a median follow-up of 5.36 years. Five-year RFS, OS and CRR were 82%, 89% and 52%, respectively. Explorative analysis revealed a cut-off LDH level of < 2.5 upper limit of normal (ULN) (n = 228) vs. ≥ 2.5 ULN (n = 123) to be associated with a significant difference concerning OS associated with 5-years OS rates of 93% vs. 83% (p = 0.001) which was confirmed in multivariate analysis (HR 2.87; p = 0.004). Furthermore, the cut-off LDH < 2.5 ULN vs. ≥ 2.5 ULN correlated with RFS and CRR associated with a 5-years RFS rate and CRR of 76% vs. 86% (p = 0.012) and 32% vs. 59% (p ≤ 0.001), respectively.CONCLUSIONS: LDH levels correlate with treatment response and survival in metastatic seminoma patients and should be considered for their prognostic stratification.

KW - Adolescent

KW - Adult

KW - Aged

KW - Humans

KW - L-Lactate Dehydrogenase/blood

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Prognosis

KW - Retrospective Studies

KW - Seminoma/blood

KW - Survival Rate

KW - Testicular Neoplasms/blood

KW - Young Adult

UR - http://www.scopus.com/inward/record.url?scp=85109030820&partnerID=8YFLogxK

U2 - 10.1007/s00345-021-03635-3

DO - 10.1007/s00345-021-03635-3

M3 - Journal article

C2 - 33683412

SN - 0724-4983

VL - 39

SP - 3407

EP - 3414

JO - World Journal of Urology

JF - World Journal of Urology

IS - 9

ER -

The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this